GEO for CBD and Regulated Wellness Brands: Visibility When Every Ad Platform Says No

Most ecommerce brands treat organic search as one channel among several. If it underperforms, budget moves to paid social, or to search ads, or to a marketplace.

CBD brands do not have that option. Paid search restricts the category heavily, paid social restricts it further, several major platforms prohibit it outright, and affiliate and influencer routes carry disclosure obligations that add friction. What remains is organic search, AI answers, email to an audience you already have, and retail placement.

That changes the calculation entirely. A visibility problem that would be a nuisance elsewhere is close to existential here, and a page that fails to get cited is not a missed opportunity, it is a missing channel.

The compensating fact is that every competitor faces the same constraint, and most of them are handling it badly.

What the Paid Lockout Actually Changes

Four consequences follow, and they are strategic rather than tactical.

Content becomes the acquisition channel rather than a support function, which justifies a level of investment that would look excessive in an unrestricted category. Publishing 40 substantial pages is not a content programme here, it is a customer acquisition programme, and the correct comparison is not against another content budget but against the 6 figures of paid spend the category cannot access.

Compounding matters more. Paid traffic stops the day the budget stops; a page that gets cited keeps working. In a category where you cannot buy a spike, the slow-compounding asset is the only asset.

Trust content carries more weight because the buyer arrives more sceptical. The category has a documented history of mislabelled products, so evidence of what is actually in the bottle does more work here than anywhere else in this series.

And entity building has to be deliberate, because the passive mechanisms that build an entity in other categories, mainstream directory listings, mainstream press coverage, marketplace presence, are partly closed.

Our post on robots.txt for AI crawlers is worth acting on early here, because if retrieval is your channel then crawler access is your distribution.

The Claims Ceiling

The regulatory position is strict and widely misunderstood.

The FDA has stated that it is unlawful to market CBD by adding it to a food or by labelling it as a dietary supplement, and it has issued warning letters over disease claims. Separately, the FTC's Health Products Compliance Guidance requires competent and reliable scientific evidence for health benefit claims, and the FTC has brought enforcement actions in this category specifically.

The practical content rules follow from that.

• Avoid disease claims entirely, including implied ones through blog titles, testimonials and category names.
• Where you describe research, describe the research rather than asserting the outcome. Studies have examined a compound for a purpose is a different sentence from the compound does the thing.
• Keep the qualifier inside the claim sentence, because summarisation separates a claim from a disclaimer positioned elsewhere and keeps the claim.
• Do not let a customer testimonial make the claim your copy avoids, since that is the most common route to an enforcement letter.
• Direct health decisions to a clinician, consistently and specifically.

As in supplements, the compliant sentence carries a compound, a concentration and a hedge, which makes it more specific than the non-compliant version and therefore more citable. Our post on YMYL trust signals covers how that scrutiny operates.

Certificates of Analysis as the Trust Backbone

In a category with a documented mislabelling history, the certificate is the product claim.

• Publish a certificate for every batch, indexed by the batch number printed on the bottle, so a customer holding lot 2411 can find lot 2411 rather than a representative sample.
• Name the laboratory and state whether it is accredited, with the accreditation named.
• Publish potency results with the actual milligram figures, not just a pass. A batch labelled 1,000 milligrams that assays at 940 is within a normal tolerance and saying so plainly is more trustworthy than publishing only the label figure.
• Publish the full panel: cannabinoid profile, THC content, heavy metals, pesticides, residual solvents and microbials.
• Publish the test date, and make sure current stock links to a current certificate rather than one from 2 years ago. A certificate dated more than 12 months before the product was made is not evidence about that product.
• Publish an HTML summary of each certificate alongside the PDF, since a PDF behind a lookup form contributes nothing to retrieval.

That final point is the single most common implementation error in the category. Brands invest real money in testing and then publish the results in the least readable format available. A batch page stating the laboratory, the date, the measured potency and the panel results as text is both more useful to a buyer and visible to every engine.

Explain how to read a certificate too. Most buyers do not know what a cannabinoid profile shows or what a limit of quantitation means, and the brand that teaches them owns an entire query set.

Legal Status Published as Data

Can I buy this where I live is a high-intent query with a genuinely complicated answer, and almost nobody publishes it.

• Publish where you ship, as a text list, with exclusions named.
• Explain the federal framework plainly, including the 0.3 percent THC threshold on a dry weight basis that has defined hemp since the 2018 Farm Bill and is administered through the USDA programme.
• Explain that state rules differ from the federal position and that some states restrict specific product types.
• Publish product-type differences, since rules for topicals, ingestibles and inhalables diverge.
• Address international shipping plainly, which for most brands means stating that you do not.
• Date the page and re-verify on a schedule, since this body of law changes and a stale page gives a confidently wrong answer.

Do not attempt to give legal advice. Describe your own shipping policy, describe the framework accurately, and direct specifics elsewhere. That is both safer and more useful than the vague statements the category currently publishes.

Dosage and Usage Guidance Inside the Line

Dosage is the most asked question and the most avoided answer.

• State the milligrams per serving and per container, plainly, with the serving size defined.
• Explain how to calculate a serving from a tincture, with the arithmetic shown. A 750 milligram bottle containing 30 millilitres holds 25 milligrams per millilitre, so a half dropper of 0.5 millilitres delivers about 12.5 milligrams. That is 3 lines of maths most first-time buyers cannot do from the label alone.
• Explain onset and duration by delivery format, in minutes and hours, which is factual rather than a health claim. A sublingual tincture, a capsule and a topical behave differently on all 3 counts and buyers pick a format without knowing that.
• Explain the start-low-and-adjust approach without prescribing an outcome.
• Explain bioavailability differences between formats factually.
• Explain interaction considerations by pointing to documented literature and directing the decision to a clinician.

The line to hold is between describing the product and promising a result. Milligrams per serving, onset time and duration are product facts. What it will do for a condition is a claim. Publishing the first set fully, while declining the second, produces content that is both compliant and considerably more useful than the vagueness that dominates the category.

Sourcing, Extraction and Spectrum

The technical story is a genuine differentiator and it is usually reduced to 3 words on a label.

• State where the hemp is grown, at farm or region level, and whether it is certified organic.
• Name the extraction method and explain what it means for the finished product.
• Explain full spectrum, broad spectrum and isolate accurately, including the THC implication of each. A full spectrum product can legally contain up to 0.3 percent THC, a broad spectrum aims for none detectable, and an isolate is a single compound, which are 3 genuinely different products sold under 1 category name.
• State the carrier oil and other ingredients in full.
• State the manufacturing standard the facility operates to and whether it is audited.
• Explain shelf life and storage in real terms, such as 12 months unopened and 6 months after opening when kept away from heat and light, which is a real product question nobody answers.

The spectrum explanation is worth building as a dedicated page. It is a definitional query with high volume, it is currently answered by publishers, and a brand that explains it accurately, including the cases where a trace THC content matters for a buyer subject to testing, is answering a question with real consequences.

Reviews Under Advertising Restriction

Reviews carry extra risk here because a testimonial can make a claim your copy carefully avoided.

• Moderate for disease claims, and say publicly that you do and why.
• Do not incentivise reviews in ways that require disclosure you are not making.
• Never fabricate, since the patterns are detectable and in a trust-poor category the reputational cost is severe. Our post on synthetic reviews covers what gets caught.
• Publish genuine reviews including critical ones, since a set of 400 reviews averaging 4.9 with no substantive criticism reads as curated rather than as good.
• Respond publicly and factually to critical reviews, which demonstrates the behaviour engines read as trustworthy.

Building the Entity Without Directories

Entity resolution is harder here because several of the usual mechanisms are closed, so the work has to be deliberate.

• Keep the brand name, founding date, location and description identical everywhere they appear.
• Publish thorough About, team and contact pages with real people and verifiable detail.
• Publish organisation markup with consistent identifiers.
• Pursue the industry and trade coverage that is open to you, since category press is available even where mainstream press is not.
• Build presence on the platforms that accept the category, and keep the descriptions consistent across all of them.
• Publish original data, testing summaries and category research, because a brand that produces citable material becomes an entity through being referenced.

Our guides to E-E-A-T and the brand authority stack cover the properties that make an entity resolvable, and in this category each one has to be earned deliberately rather than accumulated passively.

Common Mistakes

• Certificates published only as PDFs behind a lookup form. Real money spent on testing, made invisible.
• Certificates not indexed by batch. A buyer holding a bottle cannot check theirs, which is the whole point.
• Disease claims arriving through testimonials. The most common route to an enforcement letter.
• Qualifiers in a separate paragraph from the claim. Extraction keeps the claim and drops the qualifier.
• No jurisdiction content. A high-intent query with a complicated answer, unanswered.
• Dosage avoided entirely. Milligrams, onset and duration are product facts, not claims.
• Spectrum terms used loosely. The category's biggest point of confusion, and a real issue for anyone subject to testing.
• Passive entity building. The usual mechanisms are partly closed, so nothing accumulates by default.

Implementation Sequence

1. Confirm crawler access is configured correctly, since retrieval is effectively the channel.
2. Publish an HTML certificate summary page per batch, indexed by the number printed on the bottle, with laboratory, date, potency and full panel results as text.
3. Publish a guide to reading a certificate of analysis.
4. Audit every claim on the site and rewrite so the qualifier sits inside the claim sentence, with disease language removed including implied forms.
5. Moderate reviews for claims and publish your moderation policy.
6. Publish shipping jurisdictions as text, with the federal framework explained accurately, product-type differences noted and a verification date.
7. Publish dosage facts: milligrams per serving and container, serving calculation, onset and duration by format.
8. Publish sourcing, extraction, spectrum, carrier ingredients, facility standard and shelf life, and build the spectrum explainer as a dedicated page.

Frequently Asked Questions

Why does organic and AI visibility matter more for CBD than for other categories?

Because most paid channels are closed to the category, so there is no budget lever to pull when visibility falls short. Content is the acquisition channel rather than a support function, which changes both the investment case and the tolerance for pages that fail to earn citations.

How should certificates of analysis be published?

As an HTML page per batch, indexed by the batch number on the bottle, stating the laboratory, accreditation, test date, measured potency in milligrams and the full contaminant panel as text. The PDF can sit alongside, but a PDF behind a lookup form contributes nothing to how the brand is understood.

Can we publish dosage guidance without making a health claim?

Yes, provided you publish product facts rather than outcomes. Milligrams per serving, how to measure a dropper, onset time and duration by format are factual. What the product will do for a specific condition is a claim, and the distinction is where the line sits.

Do we need to publish legal status by state?

You need to publish where you ship and explain the framework accurately, with product-type differences noted and a verification date. Avoid giving legal advice, but do not leave a high-intent question unanswered while competitors leave it unanswered too.

How do you build brand authority when directories exclude the category?

Deliberately. Identical brand details everywhere, thorough and verifiable About and team pages, organisation markup, category and trade press, presence on platforms that accept you, and original data worth citing. What accumulates passively elsewhere has to be constructed here.